Published in Physician Law Weekly, October 11th, 2006
1) Completion of the accrual and treatment phase for all 36 patients enrolled in the U.S. phase I/II multicenter long bone fracture clinical trial.
2) Receipt of a local German human pharmaceuticals manufacturing license for the production of the company's TRC-based cell products for clinical use in compliance with German law and E.U. clinical trial directives. The newly licensed manufacturing facility was established as a collaboration at the Fraunhofer Institute for Interfacial Engineering and Biotechnology in Stuttgart, Germany,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly